Home › Compare › NGKIF vs ABBV
NGKIF yields 2.16% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, NGKIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NGKIF + ABBV for your $10,000?
NGK Insulators, Ltd., together with its subsidiaries, manufactures and sells electric power related equipment in Japan, North America, Europe, and Asia. The company operates through Environment Business, Digital Society Business, and Energy & Industry Business segments. It offers energy storage systems, including NAS batteries; suspension, long rod, station post, hollow, and pin post insulators; HONEYCERAM, a component for exhaust gas purification; diesel particulate filters that eliminates particulates in the exhaust gas emitted from diesel automobiles; and NOx sensors, which measures nitrogen oxide concentration in motor vehicle exhaust gas. The company also provides metal-related products, such as beryllium copper products, copper-nickel-tin alloy products, molds, and related parts; and various electronic components, such as piezoelectric micro actuators, high frequency components, and mold-cast ceramics, as well as EnerCera, a chip-type ceramic rechargeable battery. In addition, it offers ceramics for semiconductor manufacturing equipment, including ceramic heaters, electrostatic chucks, and components; and industrial process products, such as heating systems, kiln furniture and refractories, ceramic membranes and separators, glass-lining products, high temperature dust collectors, ceramic and vacuum pumps, radioactive waste treatment equipment, and gas analyzers, as well as C1 home-use water Purifiers. The company was incorporated in 1919 and is headquartered in Nagoya, Japan.
Full NGKIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.